BHC(SH:600721) Sou Hu Cai Jing·2025-07-30 08:36Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Baihua Pharmaceutical, indicating a positive trend in revenue and net profit growth [1] - As of July 30, 2025, Baihua Pharmaceutical's stock closed at 8.48 yuan, reflecting a 2.17% increase with a turnover rate of 12.58% and a trading volume of 483,300 hands, amounting to a transaction value of 409 million yuan [1] - The company reported total operating revenue of 96.91 million yuan for Q1 2025, representing a year-on-year growth of 6.65%, while the net profit attributable to shareholders was 20.72 million yuan, up 0.28% year-on-year [1] Group 2 - Baihua Pharmaceutical has a current liquidity ratio of 1.979 and a quick ratio of 1.624, indicating a strong short-term financial position, with a debt-to-asset ratio of 30.45% [1] - The company has made investments in 12 enterprises and participated in 16 bidding projects, showcasing its active engagement in business expansion [2] - Baihua Pharmaceutical holds 16 trademark registrations and has obtained 6 administrative licenses, reflecting its commitment to intellectual property and regulatory compliance [2]